This program is a live-streamed expert virtual roundtable on biosimilars in oncology, bringing experts together in a live digital forum to share their knowledge and perspectives on emerging biosimilars in oncology for an actively engaged online audience. Topics of discussion will include interchangeability of biosimilars for reference biologics, safety and efficacy data from available clinical trials, advantages and disadvantages of biosimilar use in oncology, federal and state guidance around the use of biosimilars, and clinician perceptions and practices in biosimilars use in oncology.
Upon completion of this program, clinicians will be able to:
Oncologists, primary care physicians, and clinicians who manage patients with cancer.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and The Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.
New York Medical College designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.
William Li, MD
Dr. Li has nothing to disclose with regard to commercial interests.
Clifford Goodman, PhD
Dr. Goodman is an employee of The Lewin Group, a business unit of Optum, which is a subsidiary of UnitedHealth Group. He also owns stock in UnitedHealth Group.
Jeffrey Crawford, MD
Dr. Crawford is a scientific advisor for Merck, Novartis, and Pfizer. He is a DSMB member for Celgene, G1 Therapeutics, Jannsen, Merrimack, and Roche. He receives grant/research support from Amgen, AstraZeneca, Bayer, Clovis, Genentech, and GTx.
Philip Lammers, MD, MSCI
Dr. Lammers serves as a consultant to Pfizer
Joshua Mann, MPH
The Angiogenesis Foundation
Mr. Mann has nothing to disclose with regard to commercial interests.
Jeffrey McRae, MS
The Angiogenesis Foundation
Mr. McRae has nothing to disclose with regard to commercial interests.
Commercial Support Acknowledgement:
We gratefully acknowledge Pfizer for their generous support of this educational activity.